Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis by Di Franco, Manuela et al.
Review Article
Asymmetric Dimethyl Arginine as a Biomarker of
Atherosclerosis in Rheumatoid Arthritis
Manuela Di Franco , Bruno Lucchino , Fabrizio Conti , Guido Valesini,
and Francesca Romana Spinelli
Dipartimento di Medicina Interna e Specialità Mediche-Reumatologia, Sapienza Università di Roma, Rome, Italy
Correspondence should be addressed to Bruno Lucchino; lucchino.b@gmail.com
Received 13 September 2017; Accepted 27 November 2017; Published 18 January 2018
Academic Editor: Mirella Giovarelli
Copyright © 2018 Manuela Di Franco et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Cardiovascular disease is the main cause of morbidity and mortality in rheumatoid arthritis (RA). Despite the advent on new drugs
targeting the articular manifestations, the burden of cardiovascular disease is still an unmet need in the management of RA. The
pathophysiology of accelerated atherosclerosis associated to RA is not yet fully understood, and reliable and specific markers of
early cardiovascular involvement are still lacking. Asymmetric dimethylarginine is gaining attention for its implication in the
pathogenesis of endothelial dysfunction and as biomarkers of subclinical atherosclerosis. Moreover, the metabolic pathway of
methylarginines offers possible targets for therapeutic interventions to decrease the cardiovascular risk. The purpose of this
review is to describe the main causes of increased methylarginine levels in RA, their implication in accelerated atherosclerosis,
the possible role as biomarkers of cardiovascular risk, and finally the available data on current pharmacological treatment.
1. Introduction
Patients with rheumatoid arthritis (RA) have a significantly
higher risk of cardiovascular diseases (CVD) compared to
general population, comparable to patients with diabetes
mellitus or non-RA subjects 10 years older [1]. In RA
patients, cardiovascular events account for over 50% of the
excess premature mortality [2]. Accelerated atherosclerosis
plays a pivotal role in the pathogenesis of RA-related CVD:
indeed, in RA patients, the atherosclerotic process starts in
the early phases of the disease and it is determined by both
an increased prevalence of traditional risk factors and the
inflammatory nature of RA itself [3, 4]. The systemic inflam-
mation has a major role in the pathogenesis of accelerated
atherosclerosis. Proinflammatory cytokines involved in the
pathogenesis of RA, such as TNF, IL-1, and IL-6, are also
involved in the development and in the progression of
atherosclerotic plaque. The first step in plaque development
is the activation of endothelial cells and the induction of
endothelial dysfunction (ED) by proinflammatory cyto-
kines. The proatherogenic and prothrombotic endothelium
is characterized by upregulation of adhesion molecules,
raised vascular permeability, cytokine and chemokine
expression, and reduced production of vasodilatory mole-
cules, such as nitric oxide [5]. ED is the earliest, reversible,
preclinical phase of plaque development, leading to the
accumulation of lipoproteins and inflammatory cells in the
subendothelial layer and to subsequent plaque formation
[5]. Other than activating endothelial cells, TNF and IL-6
activate monocytes and immune cells contributing to the
progression of the atherosclerotic disease, until rupture and
thrombotic complication of the plaque [6]. There is a grow-
ing interest around the prevention of CVD in RA patients,
although there is no clear evidence that any intervention
can actually reduce that risk [7]. Early identification of ED
may allow clinicians to characterize patients with subclinical
atherosclerosis, establishing early risk factor modification
or pharmacological intervention [5]. The imbalanced pro-
duction of endothelial vasoactive mediators is a key step
in the development of ED. Nitric oxide (NO) is the main
endothelial-derived vasodilatory and antiproliferative mole-
cule, inhibiting activation and vessel wall adhesion of
Hindawi
Mediators of Inflammation
Volume 2018, Article ID 3897295, 13 pages
https://doi.org/10.1155/2018/3897295
leukocytes and platelets [8]. The impaired ability of endothe-
lial cells to produce NO is a main driver of ED. Dysregulation
of other vasoactive mediators of NO metabolism predispose
to subsequent pathological abnormalities such as platelet acti-
vation, abnormal fibrinolytic activity, lipoprotein deposition,
and oxidative stress: all these modifications contribute to
impaired vascular integrity [5, 9]. The role of endogenous
inhibitors of NO synthase (NOS) activity in the induction of
ED has gained the attention of rheumatologists. Asymmetric
dimethylarginine (ADMA) is an analogue of L-arginine—the
precursor of NO—naturally released in biological fluids fol-
lowing proteolysis; it inhibits NO synthesis by competing
with L-arginine at the active site of NOS [10]. ADMA
emerged as novel markers of ED and cardiovascular risk
in RA [11]. The aim of this review is to summarize the
available data on the role of ADMA in the pathogenesis of
ED in RA patients, its role as potential biomarkers of
CVD risk, and the possible therapeutic interventions.
2. Methylarginine Metabolism
Dimethylarginines are naturally occurring endogenous prod-
ucts of the degradation of methylated proteins. Methylation
of arginine residues is a posttranslational modification cata-
lyzed by a family of enzymes called protein arginine methyl-
transferases (PRMTs) which use S-adenosylmethionine as
source of methyl groups; methylation of arginine is a
two-step process of monomethylation [12, 13]. The first
methylation leads to the formation of monomethylarginine
(MMA), while the second one can produce either symmet-
ric dimethylarginine (SDMA) or ADMA, according to the
PRMT isoform involved in the methylation reaction [14].
After their proteolysis, MMA, SDMA, and ADMA are
released in the cytosol, where the asymmetric methylargi-
nines (MMA and ADMA) inhibit NOS activity by competing
with L-arginine for the active site of the enzyme [15].
Cationic amino acid transporters (CATs) are the transmem-
brane enzymes which carry out methylarginines and arginine
from the cellular cytosol to extracellular fluids and then in the
bloodstream [16]. In physiological conditions, intracellular
levels of arginine are much higher than those required for
NOS activity; however, intravenous supplementation of argi-
nine can increase endothelial-dependent vasodilatation [17].
This apparently incongruous phenomenon is called “arginine
paradox”: several hypotheses have been proposed to explain
this effect. The activity of the enzyme arginase, which
converts arginine in ornithine and urea, may reduce the
availability of arginine, decreasing NOS activity. However,
arginine is converted by NOS in an intermediate state, the
hydroxy-L-arginine, which inhibits arginase, increasing sub-
strate bioavailability for NOS. Another possible explanation
is the competitive occupation of CATs by arginine excess
for intracellular space transportation instead of other cat-
ionic amino acids [17]. CATs and NOS are located in the
plasmatic membrane caveolae, ensuring a stable supply of
the substrate (i.e., arginine) from the plasmatic compartment
[18]. A relative abundance of plasmatic arginine may over-
take NOS inhibition by raising intracellular arginine/ADMA
ratio in the strict proximity of NOS [19]. However, using the
same transporter, plasmatic ADMA may also gain a selective
access to NOS, thus reducing NO bioavailability and explain-
ing the association with the ED and, subsequently, with the
increase in cardiovascular risk [16]. Once in the circulation,
methylarginine can be eliminated through renal excretion
or tissue catabolic pathways [13]. About 20% of ADMA is
removed from plasma by the kidney while SDMA is mostly
excreted unmodified through the urine [20]. The main
pathway for asymmetric methylarginine catabolism is the
hydrolytic reactionmediated by dimethylarginine dimethyla-
minohydrolase (DDAH)enzymeswhich catalyze thedegrada-
tion ofMMAandADMA to citrulline andmonomethylamine
or dimethylamine, respectively [21]. Different tissues and
cells express DDAH including heart, endothelium, kidney,
lung, pancreas, liver, brain, and placenta as well as macro-
phages and neutrophils; however, ADMA is mostly catalyzed
by the kidney and liver [22, 23]. A further catabolic pathway
for both symmetric and asymmetric methylarginines is the
transamination mediated by alanine-glyoxylate aminotrans-
ferase; however, the contribution of transamination to
ADMA metabolism has not been fully investigated [24].
The methylarginine metabolism is depicted in Figure 1.
3. Physiopathology of ADMA and Endothelial
Dysfunction in Rheumatoid Arthritis
3.1. Factors Affecting ADMA Levels in RA Patients. Different
mechanisms can account for the increase in ADMA levels
detected in RA patients. The inducible NOS (iNOS) is an
isoform that can be induced in various cellular types under
inflammatory stimuli; iNOS has a crucial role in the intracel-
lular clearance of pathogens and in the vasodilatation of
inflamed tissues [25]. However, the increased production of
NO by iNOS, primed by inflammatory cytokines, leads to
an S-nitrosylation of reactive cysteine in DDAH, inhibiting
ADMA catabolism, thus increasing its levels and lastly
inhibiting all three isoforms of NOS [26]. In vitro studies
on endothelial cells demonstrated that TNF, a cytokine play-
ing a key role in RA pathogenesis, exerts an inhibitory effect
on DDAH leading to the impairment in ADMA degradation
[27]. In RA patients, free radicals and nitrotyrosine produced
by rheumatoid synovia as well as by the reduced expression
of DDAH enzyme in the hypoxic environment of inflamed
synovia may further contribute to DDAH inhibition and rise
in plasmatic ADMA levels [28–30]. Another explanation for
the high ADMA levels is an increase in its production by
PRMT activity: Böger et al. described an enhanced produc-
tion of ADMA in endothelial cells exposed to native and
oxidized LDL (oxLDL), partially due to enhanced PRMT
gene expression [31]. oxLDL levels are higher in RA patients
than in healthy subjects because of the oxidative stress
coexisting with the inflammatory state [32, 33]. Moreover,
other posttranslational modifications of LDL may also
account for NO uncoupling [34]. In the rheumatoid syno-
via, endothelial cells undergo a phenotypic change charac-
terized by an increase in activation, angiogenesis, and
apoptosis [35]. The increased turnover of endothelial cells
as well as the increased number of proliferating cells
associated with angiogenetic microenvironment of the
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inflamed joint may be a source of methylarginines. ADMA
production is enhanced in apoptotic and senescent endothe-
lial cells, as a result of methylated protein turnover [36].
Patients with RA have a high basal level of insulin and a
tendency toward insulin resistance which is associated with
the inflammatory status and seems to be reverted by TNF
inhibitors [37, 38]. Proinflammatory cytokines such as TNF
and IL-6 prevent muscular glucose uptake and induce lipoly-
sis in adipocytes, leading to an impaired plasmatic glucose
regulation; moreover, free fatty acids released by stimulated
adipocytes determine a positive feedback loop both by
inducing an insulin-resistant phenotype of skeletal muscle
and liver and by stimulating TNF and IL-6 production by
macrophages [39, 40]. In diabetic patients, both increased
and decreased levels of ADMA were reported [41, 42].
Chronic hyperglycemia increases ADMA levels by inhibiting
DDAH activity [43]. On the contrary, insulin upregulates
CAT expression in various cell types [44]. In healthy subjects
and in type 1 diabetic patients, acute hyperinsulinemia
reduces ADMA levels, probably increasing the cellular
uptake related to CAT regulation [45, 46]. Raising the
production of ADMA (via DDAH inhibition) and increasing
cellular uptake (via CAT upregulation), insulin resistance
may contribute to ADMA-mediated NOS inhibition [16].
Homocysteine (Hcy) is a sulfhydryl-containing amino
acid mainly produced from the essential amino acid methio-
nine. Several factors affect Hcy levels, including age, sex,
lifestyle factors (coffee consumption, smoking habit, physical
activity, and alcohol), genotype of the enzymes involved in
Hcy catabolism, drugs and diseases interfering with its
metabolism, and most importantly group B vitamins (folic
acid, pyridoxine, and cobalamin) [47]. Hyperhomocysteine-
mia (HHcy) is a well-known risk factor for CVD in general
population and in patients with RA [48, 49]. Some authors
suggested a link between HHcy and increased ADMA levels;
indeed, Hcy inhibits DDAH activity and the endoplasmic
reticulum stress response in the dysfunctional endothelium
seems to increase proteolysis, and thus ADMA levels [50,
51]. In RA patients, several factors contribute to the increase
in Hcy serum levels. Chronic inflammation enhances
immune cell turnover increasing the folate requirement,
and the use of methotrexate contributes to folate deficiency
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Figure 1: Metabolic pathways of methylarginines. S-AdoMet: S-adenosyl-l-methionine; S-AdoHcy: S-adenosylhomocysteine; PRMT: protein
arginine methyltransferases; MMA: monomethyl arginine; ADMA: asymmetric dimethyl arginine; SMDA: symmetric dimethyl arginine;
CAT: cationic amino acid transporter; DDAH: dimethylarginine dimethylaminohydrolase; NOS: nitric oxide synthase.
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by inhibiting the enzyme dihydrofolate reductase [52, 53].
The reduced bioavailability of the methylenetetrahydrofolate,
the key substrate of methylenetetrahydrofolate reductase,
limits the conversion of Hcy to methionine, causing HHcy
[53]. The link between NO metabolism and HHcy is not
completely clear since Hcy-lowering agents seem not to sig-
nificantly affect ADMA levels [54].
3.2. Linking ADMA to Endothelial Dysfunction in RA.
Normal endothelium is responsible for many physiological
functions needed to maintain vascular integrity, such as
regulation of vascular tone and anticoagulating and anti-
inflammatory functions [55]. NO is a key mediator of many
functions of a healthy and functional endothelium, and
consequently, the impaired ability to produce NO is a
main feature of ED [56]. A dysfunctional endothelium is
characterized by cytokine and chemokine production,
adhesion molecule expression, platelet activation, abnormal
fibrinolytic activity, lipoprotein deposition, and immune
cell migration in the subendothelial layer leading to the
early and subclinical phases of the atherosclerosis and
driving all the steps of CVD until acute complications
[5, 8, 9, 55].
Methylarginines affect endothelial function in different
ways. Asymmetric methylarginines inhibit the three isoforms
of NOS, reducing the NO production [15]. Furthermore,
ADMA and MMA can compete with arginine for transmem-
brane transport through CAT, reducing the availability of the
substrate for NO synthesis [57, 58]. Besides the interference
with arginine-dependent NO production, ADMA determine
“NOS uncoupling,” a shift in NOS enzymatic activity from
reductase to oxidase [59]. In the absence of its substrate,
NOS transfers electrons to molecular oxygen, instead of
arginine, leading to the formation of superoxide, instead of
NO [59]. Superoxide is a free radical which rapidly combines
with NO producing peroxynitrite, a highly reacting interme-
diate and powerful source of oxidative stress that entails
DNA and protein oxidation and at high concentration,
cytotoxicity [60]. Therefore, superoxide and peroxynitrite
produced by ADMA-related NOS uncoupling contribute to
oxidative stress and endothelial cell dysfunction [61].
Endothelial progenitor cells (EPCs) are bone marrow
derived, circulating endothelial precursors able to differen-
tiate in situ in functional endothelium, contributing to
endothelial injury recovery and limiting atherosclerotic
plaque formation; in the light of their repairing effect,
EPCs are biomarkers of endothelial health [62]. A reduced
number of circulating EPCs has been described in a num-
ber of conditions associated with an increased cardiovas-
cular risk, including RA [63, 64]. In patients with RA,
different authors observed an inverse correlation between
ADMA levels and the number of circulating EPCs which
can be reversed by TNF inhibitors [64–67]. Since NO is a
key regulator of EPC migration and differentiation, lowering
endogenous production of NO by the endothelium, ADMA
can markedly reduce the mobilization and function of EPCs,
impairing the protective effect [67, 68]. Figure 2 summarizes
the physiopathology of ADMA in ED development in
patients with RA.
4. ADMA as Biomarker of Cardiovascular
Risk in Rheumatoid Arthritis
In the last years, the potential role of ADMA as a biomarker
of cardiovascular risk has been investigated in several condi-
tions. Recently, a meta-analysis of about 20,000 nonoverlap-
ping participants enrolled in 22 cohort studies and long-term
follow-up demonstrated an association between circulating
levels of ADMA and cardiovascular outcomes, including
coronary heart disease and stroke [69]. ADMA was also cor-
related with noninvasive markers of subclinical atherosclero-
sis such as flow-mediated dilation (FMD) and intima-media
thickness (IMT). Brachial artery FMD is a noninvasive
method to evaluate NO-mediated flow response to subis-
chemic stimuli. FMD is a useful marker of CVD risk since
it correlates with more invasive measurement of ED, with
cardiovascular risk, and with coronary artery vasodilatory
function [70]. In healthy subjects, elevated ADMA levels
are associated with a reduced FMD, suggesting that ADMA
may represent a biomarker of ED [71, 72]. In RA patients,
the decrease of the endothelium-dependent macrovascular
function starts to be evident within the first year of the dis-
ease; some authors detected an association with disease activ-
ity, not confirmed by others, and with serology [73, 74]. Some
reports suggested an inverse correlation between ADMA
levels and FMD, not confirmed by other studies [66, 75–77]
(Table 1).
Ultrasonographic evaluation of carotid IMT is a reliable
marker of cardiovascular outcome correlating with tradi-
tional risk factors and with the incidence of clinical cardio-
vascular events [78, 79]. A meta-analysis of the literature
published in 2015 reported an increased carotid IMT with a
higher prevalence of carotid plaque in RA patients compared
to control subjects [80]. A meta-analysis of over 6,000
patients showed a positive relation between carotid IMT
and ADMA, suggesting a role for the latter as a serological
biomarker of cardiovascular risk [81]. As for RA, literature
data seems not to confirm the association between carotid
IMT and ADMA levels [77, 82–84] (Table 1). A single recent
study, investigating biomarkers of micro- and macrovascular
function in 197 RA patients, demonstrated a significant
correlation between ADMA levels and noninvasive markers
of endothelial dysfunction, in those patients showing a high
disease activity: the authors showed a positive correlation
between ADMA levels and cIMT and between arterial stiff-
ness and ADMA/SDMA ratio, especially in patients with
high inflammatory markers [85].
The studies investigating a possible association between
markers of disease activity and ADMA led to conflicting
results. A few studies on RA patients demonstrated a positive
correlation between ADMA levels and C-reactive protein
and disease activity score (DAS28) values, suggesting a
link between a high inflammatory state, ADMA levels,
and CVD in active RA; however, other studies failed to
replicate these results [77, 82, 86–89]. Similarly, some
reports described an association between anticitrullinated
peptide antibodies (ACPA) titer and ADMA levels, espe-
cially in patients with early disease [87, 90, 91]. In RA
patients, ADMA showed a positive correlation with Hcy
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levels and it is associated with insulin resistance (the
homeostasis model assessment (HOMA) being a strong
predictor of ADMA serum levels) [92, 93]. Finally, ADMA
serum levels correlate with other markers of endothelial
health status, such as EPCs: the reduction in circulating
EPCs, correlating with high plasmatic level of ADMA
and high DAS28 values, was restored by a short course
of TNF inhibitors [65]. In summary, these observations
strongly suggest a possible role of ADMA as a reliable bio-
marker of early atherosclerosis in RA patients, especially
in the context of an active disease.
ADMA levels start increasing in the early phase of
disease, and the introduction of disease-modifying antirheu-
matic drug (DMARD) treatment seems to decrease the levels
compared to those observed in the control group [77]. In a
study on 20 early, untreated RA patients, our group
demonstrated that therapeutic intervention with conven-
tional synthetic DMARDs or TNF inhibitors significantly
reduced ADMA serum levels [77]. Even in long-standing
RA patients, the treatment with TNF inhibitors seems to
reduce ADMA levels: this effect was shown in a study on 33
RA patients starting etanercept or adalimumab but was not
confirmed by other authors [66, 83, 84, 91]. Table 1 summa-
rizes the main findings of the studies investigating ADMA
serum levels in the context of RA [65, 66, 75–77, 82–98].
The heterogeneity of methods used to assess subclinical
atherosclerosis and the different contributions of traditional
and disease-related risk factors in a complex disease such as
RA may account for the lack of concordance of the results
and limit the usefulness of ADMA as a marker for atheroscle-
rotic risk stratification. In this regard, a cutoff level of ADMA
defining a dysfunctional endothelium could be helpful.
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Figure 2: Mechanisms of ADMA-induced endothelial dysfunction in rheumatoid arthritis. The inflammatory microenvironment of the
inflamed synovia produces cytokines and reactive oxygen species which directly stimulate PRTM and inhibits DDAH in endothelial cells,
increasing ADMA production. Cytokines influence metabolically active tissues like skeletal muscle and adipocytes, inducing insulin
resistance. This can generate a positive feedback loop, with an increased release of cytokines from macrophages and increased ADMA
production in endothelial cells as well. The increased levels of oxidated lipoproteins, as a consequence of the oxidative stress linked to
synovitis, furthermore contribute to ADMA synthesis, as well as the increased apoptosis of endothelial cells in inflamed synovium. At last,
folate deficit, related to the increased cellular turnover, to the oxidation of folate from reactive oxygen species and to the methotrexate
treatment, induces an increased generation of homocysteine, which contributes to ADMA increase. ADMA increase can induce
endothelial dysfunction, oxidative stress, and EPCs inhibition, conducing atherosclerosis development and cardiovascular complications.
PRMT: protein arginine methyltransferases; DDAH: dimethylarginine dimethylaminohydrolase; NOS: nitric oxide synthase; ADMA:
asymmetric dimethyl arginine; EPCs: endothelial progenitor cells; MTX: methotrexate; Hcy: homocysteine; CVD: cardiovascular disease.
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5. Possible Therapeutic Intervention
Since methylarginines play a key role in the physiopathology
of ED and ADMA levels have been strictly associated to car-
diovascular risk, several pharmacological interventions have
been investigated on the possible effect on ADMA levels
and cardiovascular outcomes. However, taking into account
the wide spectrum of indications of the drugs investigated
and of the inter-study result variability, the actual relation
between ADMA level reduction and cardiovascular benefits
is still inconclusive [13]. Effect of statins on methylarginine
metabolism has been investigated in different conditions
such as diabetes, stroke, and hypercholesterolemia, demon-
strated to effectively reduce plasmatic ADMA levels in recent
controlled trials [99–101]. In vitro, statins increase the
expression of DDAH genes and the bioavailability of
tetrahydrobiopterin (BH4), which is a critical eNOS cofactor
inhibiting NOS uncoupling phenomenon [102]. A recent
Table 1: Main findings of the studies investigating ADMA in rheumatoid arthritis.
Number of RA
patients (controls)
Main findings Reference
91 (31) No correlation between ADMA and subendocardial viability ratio Anyfanti et al. [94]
201 No association between ADMA and genetic variants of the AGXT2 gene Dimitroulas et al. [95]
197
Association between microvascular function, arterial stiffness,
and cIMT and ADMA/SDMA levels in RA patients with
high inflammatory marker
Dimitroulas et al. [85]
40 (29)
Inverse correlation between ADMA and FMD; positive correlation
between ADMA and disease duration; no correlation with CRP
Sentürk et al. [88]
30 (30)
No relationship between ADMA concentration and aortic augmentation;
no difference in ADMA levels between patients and controls
Erre et al. [96]
201
Difference in ADMA levels according to MTHFR; positive correlation
between ADMA and Hcy and ESR
Dimitroulas et al. [92]
100
No correlation between ADMA and thCys at baseline and after omega-3
fatty acids, vitamin E, vitamin A, copper, and selenium, or placebo;
correlation between ADMA and arginine
Kayacelebi et al. [98]
201 Positive correlation between ADMA and ESR and ADMA and CRP Sandoo et al. [89]
33
Correlation between ADMA and DAS28; reduction of ADMA levels
after 3 months of anti-TNF
Spinelli et al. [66]
201 No significant relationship between DDAH genetic variables and ADMA levels Dimitroulas et al. [97]
17 (12) Inverse correlation between ADMA levels and circulating EPC number Spinelli et al. [65]
35 (35)
ADMA and RF have similar sensitivity and specificity in the
detection of endothelial dysfunction
Spasovski and Sotirova [91]
67 HOMA, an indicator of insulin resistance, predicts elevated ADMA levels Dimitroulas et al. [93]
48 (32)
Association between baseline PWV and ADMA but no correlation
with cIMT; anti-TNF therapy increased L-arginine/ADMA ratio
but not ADMA after 3 months
Angel et al. [84]
20 (20)
Significantly higher ADMA levels in RA than controls; significant
reduction after 12 months of treatment
Di Franco et al. [77]
35 No change in ADMA levels after 2 weeks and 3 months of anti-TNF treatment Sandoo et al. [75]
46 (50)
Higher ADMA levels in RA than in controls; correlation with CRP,
DAS28, and 8-isoprostanes
Kwaśny-Krochin et al. [86]
60 (29)
Significantly higher ADMA levels in RA compared with controls;
no correlation with demographic or disease characteristics
Sandoo et al. [83]
25 No change in ADMA levels and cIMT after treatment Turiel et al. [82]
25 (25)
Higher ADMA levels in early RA than in controls. Significant negative
correlation between ADMA levels and CFR; no correlation with IMT
Turiel et al. [90]
20
Positive correlation between ACPA and ADMA levels;
no correlation with disease activity indices
Surdacki et al. [87]
36 (20) Chronic low-dose prednisolone lower ADMA levels Radhakutty et al. [109]
ADMA= asymmetric dimethyl arginine; AGXT2 = alanine-glyoxylate aminotransferase 2; SDMA= symmetric dimethyl arginine; cIMT = carotid intimamedia
thickness; FMD= flow-mediated dilation; CRP = C-reactive protein; MTHFR =methylenetetrahydrofolate reductase; Hcy = homocysteine; ESR = erythrocyte
sedimentation rate; thCys = total L-homocysteine; DAS28 = disease activity score 28; TNF = tumor necrosis factor; DDAH= dimethylaminohydrolase;
EPCs = endothelial progenitor cells; RF = rheumatoid factor; HOMA= homeostasis model assessment; PWV= pulse wave velocity; CFR = coronary flow
reserve; ACPA= anticitrullinated peptide antibodies.
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double-blind randomized study demonstrated that supple-
mentation of oral tetrahydrobiopterin significantly improved
the endothelial function measured by FMD in a small cohort
of RA patients [103]. The authors did not investigate the
effect on ADMA levels but, considering the implication of
folate in methylarginine metabolism, an ADMA-lowering
effect could be expected. This is also supported by the
consolidated evidence of the role of folate supplementation
on plasmatic Hcy lowering, in consideration of the interplay
between HHcy and raised ADMA levels [47]. This suggests
that larger and targeted studies, addressing the potential
effect of tetrahydrobiopterin supplementation on ADMA
levels in relation to ED and risk of CVD, are desirable.
In a small study on RA patients, atorvastatin effectively
reduced arterial stiffness measured by pulse wave analysis,
without affecting acute-phase reactants [104]. The lipid-
lowering agent ezetimibe showed the ability to lower ADMA
levels and to ameliorate renal function in patients with
chronic kidney disease, probably by protecting DDAH
enzymatic site from oxidative inactivation [105]. Besides
the lipid-lowering effect, ezetimibe, as well as simvastatin,
demonstrated to reduce disease activity and C-reactive pro-
tein levels and to improve the endothelial function and the
arterial stiffness in patients with RA [106].
The evidence that lipid-lowering drugs couple an anti-
inflammatory effect with an improvement of endothelial
function, by modulation of ADMA metabolism, may suggest
a role for these drugs in the management of cardiovascular
risk associated to RA. The ADMA-lowering effect of several
other agents have been investigated in conditions different
from RA. Only few studies addressed the effects of therapeu-
tic intervention for RA on ADMA levels. Treatment with
DMARDs, especially anti-TNF agents, demonstrated a
lowering effect on ADMA levels, more pronounced in high
inflammatory conditions (patients with high levels of acute-
phase reactants) [85]. A recent meta-analysis showed that
treatment with TNF inhibitors improves endothelial function
in patients with RA [107]. It is very likely that effect of TNF
inhibitors on cardiovascular risk is multifactorial, acting on
different steps of the atherosclerotic process. Longitudinal
studies demonstrated a short-term effect of TNF inhibitors
on ADMA levels, not confirmed in studies with different
Table 2: ADMA lowering effect and possible pharmacodynamic mechanism of different drugs.
Drug Investigated conditions Hypothesized mechanism Results References
Statins
Diabetes mellitus, stroke,
hypercholesterolemia
Increase DDAH expression, increased
bioavailability of tetrahydrobiopterin
Decreased ADMA serum
levels (18–50%)
[100, 109]
Fibrate Hypertriglyceridemia
Increase DDAH activity through NF-kB
suppression via PPAR-α receptors
Uncertain effect on ADMA
serum levels, increase
L-arginine/ADMA ratio
[111]
Niacine Dyslipidemia
Depletion of methyl groups for niacine
metabolism and consequent reduction
in ADMA synthesis
Decreased ADMA serum
levels (10%)
[112]
ACE
inhibitors/ARB
Chronic
glomerulonephritis,
hypertension
Decreased NADPH oxidase upregulation
by RAA system, with consequent reduced
ROS-mediated DDAH inhibition
Decreased ADMA serum
levels (10–16%)
[113, 114]
Thiazolidinediones Diabetes mellitus
Through PPAR-γ receptor activation:
reduced insulin resistance, increased
expression of DDAH in renal tubules,
suppressed activity of NF-kB
Controversial; from no
reduction to reduction of
ADMA serum levels (10%),
possible protection against
ADMA effect
[115]
Metformin
Diabetes mellitus
Polycystic
ovarian syndrome
Partially unknown, apparently not
mediated by PRTM or DDAH
Competitive antagonist of ADMA
Decreased ADMA
serum levels (27%)
[116]
Nebivolol Hypertension
Upregulation of DDAH,
downregulation of PRTM
Decreased ADMA serum
levels (37–44%)
[117, 118]
Acetylsalicylic acid Coronary artery disease Upregulation of DDAH and eNOS
Decreased ADMA serum
levels (30%)
[119]
Estrogens Postmenopausal women Upregulation of DDAH via ERα
Decreased ADMA serum
levels (18–20%)
[120, 121]
Folate and
B group vitamins
Hypertension,
hyperhomocysteinemia,
chronic heart failure
Increased bioavailability of
methylenetetrahydrofolate
Decreased ADMA serum
levels (14%), acute decrease
during e.v. infusion
[122, 123]
α-Lipoic acid
End-stage renal disease,
diabetes mellitus
Activation and upregulation of
DDAH via STAT3
Decreased ADMA serum
levels (9%)
[124]
N-Acetylcysteine End-stage renal disease
Partially unknown,
direct activation DDAH,
or ROS scavenging
Decreased ADMA serum
levels (30%)
[125]
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follow-up [77, 83, 84]. Nevertheless, in a 12 month follow-up
study, TNF inhibitors improved the arginine/ADMA ratio
despite not impacting on ADMA absolute levels [84]. These
results imply that the modulation of ADMA metabolism
could partially account to the atheroprotective effect of
TNF inhibitors.
The effect of folate supplementation on plasmatic Hcy
is well known and some authors hypothesized an interplay
between HHcy and raised ADMA [47]. A single study on
a large population of RA patients (n = 201) demonstrated
that Hcy levels are significantly related to serum ADMA,
contrasting with previous data obtained in a smaller group
of patients [92, 98]. The relationship between ADMA and
Hcy levels is intriguing since the latter is affected by the
use of methotrexate, a milestone in the RA treatment. In
a recent study, Dimitroulas et al. demonstrated a trend
of the MTHFR polymorphism to influence ADMA levels,
with the C667T polymorphism associated to higher
ADMA levels, only at the univariate analysis [92]. Interest-
ingly, C677T polymorphism was associated with subclini-
cal atherosclerosis and CVD risk in a study on 612 RA
patients followed up for 5 and 10 years [108]. These evi-
dences may support the protective, antiatherogenic effect
of methotrexate.
A very recent study investigated the effect of low-dose
glucocorticoids on arginine metabolisms by comparing
patients who were chronically treated or not with predniso-
lone and demonstrated higher levels of ADMA and MMA
in those patients who were not taking glucocorticoids; the
authors conclude that long-term glucocorticoid treatment
could help in protecting endothelial health in RA patients
[109].
Table 2 summarizes potential therapeutic intervention
with ADMA-lowering effect.
6. Conclusion
CVD risk reduction is still an unmet need in the long-term
management of RA patients and, despite the great
improvement of RA treatment, CVD is still the main cause
of death. In 2016, the European League Against Rheumatism
(EULAR) updated the recommendations for the manage-
ment of CVD in rheumatic disease firstly published in
2009, suggesting the need for an aggressive and targeted risk
management [110]. The research agenda still includes issues
about the precise effect of antirheumatic drugs with different
modes of action and the additional value of novel biomarkers
for CVD risk prediction on CVD risk [110]. The physiopa-
thology of ED in chronic inflammatory diseases such as RA
is still largely unknown, and biomarkers to efficiently stratify
patients according to their CV risk are scant. ADMA seems
to have the potential to solve part of these issues. The
apparent physiopathological role of ADMA in endothelial
NO deficit as well as the correlation between the circulating
ADMA levels and cardiovascular outcomes suggest that
ADMA could be a good candidate for further basic research.
Moreover, better understanding the role of ADMA in ED
could also provide potential target of pharmacological
intervention to lower the cardiovascular risk in RA.
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